{"id":39047,"date":"2025-08-12T10:48:39","date_gmt":"2025-08-12T02:48:39","guid":{"rendered":"https:\/\/flcube.com\/?p=39047"},"modified":"2025-08-12T10:48:40","modified_gmt":"2025-08-12T02:48:40","slug":"huadong-medicine-inks-exclusive-deal-for-jak1-inhibitor-vc005-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39047","title":{"rendered":"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">On August 12, 2025, China-based Huadong Medicine Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced that its exclusive commercialization partnership agreement with Jiangsu Vcare PharmaTech Co., Ltd. for VC005 has officially become effective. The agreement grants Huadong Medicine exclusive commercialization rights for the oral formulation of VC005 in mainland China. Under the terms of the agreement, Huadong Medicine will make an upfront payment of 50 million yuan to Jiangsu Vcare and additional milestone payments of up to 180 million yuan upon regulatory approval.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Partnership Details<\/strong><br>Huadong Medicine will serve as the exclusive general distributor for Jiangsu Vcare within the licensed territory, responsible for the commercialization of the licensed product. Jiangsu Vcare will act as the Marketing Authorization Holder (MAH), overseeing the research and development, registration, manufacturing, and supply of the product within the licensed territory.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>VC005 Profile<\/strong><br>VC005 tablets are a novel, potent, and highly selective second-generation oral JAK1 inhibitor developed by Jiangsu Vcare. By selectively inhibiting JAK1, VC005 reduces inflammatory responses and immune cell activation. It is currently in clinical development for the treatment of inflammatory and autoimmune diseases, with ongoing Phase III trials for moderate-to-severe atopic dermatitis. VC005 has shown comparable efficacy to upadacitinib in a Phase II study and has entered Phase III clinical trials for this indication. The drug maintains strong JAK1 inhibition while reducing JAK2 inhibition selectivity, potentially addressing safety concerns associated with excessive JAK2 inhibition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u4ea7\u54c1\u72ec\u5bb6\u5546\u4e1a\u5316\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u4ea7\u54c1\u72ec\u5bb6\u5546\u4e1a\u5316\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-aa7be776-19b4-4e42-9334-0f1ecd29d632\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u4ea7\u54c1\u72ec\u5bb6\u5546\u4e1a\u5316\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\">\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u4ea7\u54c1\u72ec\u5bb6\u5546\u4e1a\u5316\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u4ea7\u54c1\u72ec\u5bb6\u5546\u4e1a\u5316\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-aa7be776-19b4-4e42-9334-0f1ecd29d632\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39049,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[65,114,887,573],"class_list":["post-39047","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-huadong-medicine","tag-she-000963","tag-vcare-pharmatech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive commercialization partnership agreement with Jiangsu Vcare PharmaTech Co., Ltd. for VC005 has officially become effective. The agreement grants Huadong Medicine exclusive commercialization rights for the oral formulation of VC005 in mainland China. Under the terms of the agreement, Huadong Medicine will make an upfront payment of 50 million yuan to Jiangsu Vcare and additional milestone payments of up to 180 million yuan upon regulatory approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39047\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China\" \/>\n<meta property=\"og:description\" content=\"On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive commercialization partnership agreement with Jiangsu Vcare PharmaTech Co., Ltd. for VC005 has officially become effective. The agreement grants Huadong Medicine exclusive commercialization rights for the oral formulation of VC005 in mainland China. Under the terms of the agreement, Huadong Medicine will make an upfront payment of 50 million yuan to Jiangsu Vcare and additional milestone payments of up to 180 million yuan upon regulatory approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39047\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-12T02:48:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-12T02:48:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China\",\"datePublished\":\"2025-08-12T02:48:39+00:00\",\"dateModified\":\"2025-08-12T02:48:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047\"},\"wordCount\":239,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1202.webp\",\"keywords\":[\"Auto-immune\",\"Huadong Medicine\",\"SHE: 000963\",\"Vcare PharmaTech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39047#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39047\",\"name\":\"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1202.webp\",\"datePublished\":\"2025-08-12T02:48:39+00:00\",\"dateModified\":\"2025-08-12T02:48:40+00:00\",\"description\":\"On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive commercialization partnership agreement with Jiangsu Vcare PharmaTech Co., Ltd. for VC005 has officially become effective. The agreement grants Huadong Medicine exclusive commercialization rights for the oral formulation of VC005 in mainland China. Under the terms of the agreement, Huadong Medicine will make an upfront payment of 50 million yuan to Jiangsu Vcare and additional milestone payments of up to 180 million yuan upon regulatory approval.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39047\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1202.webp\",\"width\":1080,\"height\":608,\"caption\":\"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39047#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China - Insight, China&#039;s Pharmaceutical Industry","description":"On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive commercialization partnership agreement with Jiangsu Vcare PharmaTech Co., Ltd. for VC005 has officially become effective. The agreement grants Huadong Medicine exclusive commercialization rights for the oral formulation of VC005 in mainland China. Under the terms of the agreement, Huadong Medicine will make an upfront payment of 50 million yuan to Jiangsu Vcare and additional milestone payments of up to 180 million yuan upon regulatory approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39047","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China","og_description":"On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive commercialization partnership agreement with Jiangsu Vcare PharmaTech Co., Ltd. for VC005 has officially become effective. The agreement grants Huadong Medicine exclusive commercialization rights for the oral formulation of VC005 in mainland China. Under the terms of the agreement, Huadong Medicine will make an upfront payment of 50 million yuan to Jiangsu Vcare and additional milestone payments of up to 180 million yuan upon regulatory approval.","og_url":"https:\/\/flcube.com\/?p=39047","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-12T02:48:39+00:00","article_modified_time":"2025-08-12T02:48:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39047#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39047"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China","datePublished":"2025-08-12T02:48:39+00:00","dateModified":"2025-08-12T02:48:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39047"},"wordCount":239,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39047#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1202.webp","keywords":["Auto-immune","Huadong Medicine","SHE: 000963","Vcare PharmaTech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39047#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39047","url":"https:\/\/flcube.com\/?p=39047","name":"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39047#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39047#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1202.webp","datePublished":"2025-08-12T02:48:39+00:00","dateModified":"2025-08-12T02:48:40+00:00","description":"On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive commercialization partnership agreement with Jiangsu Vcare PharmaTech Co., Ltd. for VC005 has officially become effective. The agreement grants Huadong Medicine exclusive commercialization rights for the oral formulation of VC005 in mainland China. Under the terms of the agreement, Huadong Medicine will make an upfront payment of 50 million yuan to Jiangsu Vcare and additional milestone payments of up to 180 million yuan upon regulatory approval.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39047#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39047"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39047#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1202.webp","width":1080,"height":608,"caption":"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39047#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39047"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39047\/revisions"}],"predecessor-version":[{"id":39050,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39047\/revisions\/39050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39049"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}